<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02610010</url>
  </required_header>
  <id_info>
    <org_study_id>2015-FXY-066-Dept. of RT</org_study_id>
    <nct_id>NCT02610010</nct_id>
  </id_info>
  <brief_title>Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma</brief_title>
  <official_title>Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma: a Phase 3 Non-inferior Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangdong Pharmaceutical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prior phase III randomized trial showed considerable survival benefit from the combined
      treatment of cisplatin-based concurrent chemotherapy and two-dimensional conventional
      radiotherapy (2DCRT) for patients with stage II (the Chinese 1992 staging system)
      nasopharyngeal carcinoma. However, since intensity-modulated radiotherapy (IMRT) was known to
      be superior to 2DCRT in local control, progression free survival and even overall survival,
      it is a pivotal question whether stage II [T1N1M0 and T2N0-1M0, based on the 2010
      International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) staging
      system] patients can still obtain significant benefit from the additional concurrent
      chemotherapy in the IMRT era.

      The investigators' retrospective study (PMID:26528755 ) indicated that low risk
      nasopharyngeal carcinoma (T1N1M0, T2N0-1M0 or T3N0M0, the 2010 UICC/AJCC staging system)
      patients who underwent IMRT could not benefit from cisplatin-based concurrent chemotherapy.
      Therefore, the investigators perform this randomized controlled trial to address this
      question, on a prudent assumption that IMRT alone was not inferior to IMRT plus concurrent
      chemotherapy in stage II patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients are randomly assigned to receive intensity-modulated radiotherapy (IMRT)
      alone or IMRT plus concurrent chemotherapy. IMRT is given as 2.0-2.30 Gy per fraction with
      five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the
      primary tumor. Concurrent chemotherapy consisted of cisplatin 100 mg/m² every 3 weeks for 3
      cycles. The primary endpoint is overall survival (OS). Secondary end points include
      failure-free survival(FFS), locoregional relapse-free survival (LRFS), distant
      metastasis-free survival (DMFS), toxic effects and quality of life. All efficacy analyses are
      conducted in the intention-to-treat population, and the safety population include only
      patients who receive their randomly assigned treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Two year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>failure-free survival</measure>
    <time_frame>two year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis-free survival</measure>
    <time_frame>two year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional relapse-free survival</measure>
    <time_frame>two year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related acute adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessing by questionnaires</measure>
    <time_frame>through study completion, an average of 5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IMRT alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensity-modulated radiotherapy without cisplatin-based concurrent chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMRT plus concurrent chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensity-modulated radiotherapy with cisplatin-based concurrent chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.</description>
    <arm_group_label>IMRT plus concurrent chemotherapy</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiotherapy</intervention_name>
    <description>Intensity-modulated radiotherapy</description>
    <arm_group_label>IMRT alone</arm_group_label>
    <arm_group_label>IMRT plus concurrent chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly histologically confirmed non-keratinizing (WHO 1991) nasopharyngeal carcinoma.

          -  Tumor staged as T1N1M0 or T2N0-1M0 (the 2010 UICC/AJCC staging system).

          -  Karnofsky scale (KPS) ≥ 70.

          -  Adequate marrow: leucocyte count ≥ 4×10E9/L, hemoglobin ≥ 110g/L and platelet count ≥
             100×10E9/L.

          -  Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase
             (AST) and bilirubin ≤ 1.5×upper limit of normal (ULN) concomitant with alkaline
             phosphatase (ALP) ≤ 2.5×ULN.

          -  Adequate renal function: creatinine clearance ≥ 60 ml/min or creatinine ≤ 1.5×ULN.

          -  Patients must give written informed consent.

        Exclusion Criteria:

          -  Prior malignancy, except adequately treated basal cell or squamous cell skin cancer,
             in situ cervical cancer.

          -  Pregnancy or lactation (consider pregnancy test in women of child-bearing age and
             emphasize effective contraception during the treatment period).

          -  History of previous radiotherapy (except for non-melanomatous skin cancers outside
             intended radiotherapy volume).

          -  Prior radiotherapy, chemotherapy or surgery (except diagnostic) to primary tumor or
             nodes.

          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose &gt;
             1.5×ULN), and emotional disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fang-Yun Xie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University Cancer Center,Guangzhou, Guangdong, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fang-Yun Xie, M.D.</last_name>
    <phone>+86-020-87342618</phone>
    <email>xiefy@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pu-Yun OuYang, M.D.</last_name>
    <phone>+86-020-87342618</phone>
    <email>ouyangpy@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang-Yun Xie, M.D.</last_name>
      <phone>+86-020-87342618</phone>
      <email>xiefy@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Pu-Yun OuYang, M.D.</last_name>
      <phone>+86-020-87342618</phone>
      <email>ouyangpy@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang LN, Gao YH, Lan XW, Tang J, Su Z, Ma J, Deng W, OuYang PY, Xie FY. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Oncotarget. 2015 Dec 22;6(41):44019-29. doi: 10.18632/oncotarget.5806.</citation>
    <PMID>26528755</PMID>
  </reference>
  <reference>
    <citation>Su Z, Mao YP, Tang J, Lan XW, OuYang PY, Xie FY. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Tumour Biol. 2016 Apr;37(4):4429-38. doi: 10.1007/s13277-015-4266-5. Epub 2015 Oct 25.</citation>
    <PMID>26499947</PMID>
  </reference>
  <reference>
    <citation>Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011 Dec 7;103(23):1761-70. doi: 10.1093/jnci/djr432. Epub 2011 Nov 4.</citation>
    <PMID>22056739</PMID>
  </reference>
  <reference>
    <citation>Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):661-8. doi: 10.1016/j.ijrobp.2010.03.024. Epub 2010 Jul 17.</citation>
    <PMID>20643517</PMID>
  </reference>
  <reference>
    <citation>Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, You R, Hua YJ, Sun Y, Ma J, Hong MH, Chen MY. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015 Nov;51(17):2587-95. doi: 10.1016/j.ejca.2015.08.006. Epub 2015 Aug 26.</citation>
    <PMID>26318726</PMID>
  </reference>
  <reference>
    <citation>Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012 Sep;104(3):286-93. doi: 10.1016/j.radonc.2012.08.013. Epub 2012 Sep 17.</citation>
    <PMID>22995588</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Fang-Yun Xie</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>NPC</keyword>
  <keyword>concurrent chemotherapy</keyword>
  <keyword>IMRT</keyword>
  <keyword>stage II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

